Nursing Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors
The Breast, 10/21/09

Stuart-Harris R et al. – We analysed the outcomes of women with metastatic breast cancer (MBC) from three randomised phase III trials of aromatase inhibitors according to oestrogen receptor (ER) and progesterone receptor (PgR) status.

Methods

Both receptors analysed in 1010 of 1870 women (54%), including 31 that were ER-/PgR-,were excluded
Of remaining 979, 726 (74%) were ER+/PgR+ but 253 were single hormone receptor positive (213 ER+/PgR-, 40 ER-/PgR+)

Results

No differences in clinical benefit or time to progression, the median overall survival of women with ER+/PgR+ tumours significantly longer than those with single HR positive tumours (800 versus 600 days)
In women with ER+ tumours, median overall survival of those with tumours that were also PgR+ was significantly longer than those that were PgR- (800 versus 625 days)